Kolexia
Meunier Mathieu Hématologie
Meunier Mathieu
Hématologie
Hôpital Nord Grenoble
La Tronche, France
63 Activités
42 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndromes myélodysplasiques Leucémies Leucémie myéloïde Leucémie aigüe myéloïde Préleucémie Leucémie myélomonocytaire chronique Myélofibrose primitive Anémie Leucémie myéloïde chronique BCR-ABL positive

Collaborateurs

Voir plus
Park Sophie
Park Sophie
Hôpital Nord Grenoble, La Tronche, France
Lefebvre Christine
Lefebvre Christine
Hôpital Nord Grenoble, La Tronche, France
Cahn Jean-Yves
Cahn Jean-Yves
Hôpital Nord Grenoble, La Tronche, France
Laribi Kamel
Laribi Kamel
Centre Hospitalier du Mans, Le Mans, France

Industries

Voir plus
B3TSI
16 collaboration(s)
Dernière en 2023
Novartis
11 collaboration(s)
Dernière en 2023
Pfizer
10 collaboration(s)
Dernière en 2023
A+A
8 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
MPO-MDS-Develp: Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes.
Essai Clinique (CHU Grenoble)   18 mars 2024
ELEMENT-MDS: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
Essai Clinique (BMS)   11 mars 2024
Cytomegalovirus detection is associated with ICU admission in non-AIDS and AIDS patients with Pneumocystis jirovecii pneumonia.
PloS one   10 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024
Mutational Profile and Dynamics of PPM1D-Mutant Clones in the Spectrum of Myeloid Disorders
65th ASH Annual Meeting Abstracts   02 novembre 2023
CPX-351 in Patients with Newly Diagnosed Post Myeloproliferative Neoplasms Acute Myeloid Leukemia
65th ASH Annual Meeting Abstracts   02 novembre 2023
Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
65th ASH Annual Meeting Abstracts   02 novembre 2023
Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms
65th ASH Annual Meeting Abstracts   02 novembre 2023
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Essai Clinique (CHU Brest)   27 octobre 2023